{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:34:57Z","timestamp":1791516897972,"version":"4.3.4"},"reference-count":233,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007338","name":"All-India Institute of Medical Sciences","doi-asserted-by":"publisher","award":["BT\/RLF\/Re-entry\/18\/2017"],"award-info":[{"award-number":["BT\/RLF\/Re-entry\/18\/2017"]}],"id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.seminoncol.2025.152390","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:47:33Z","timestamp":1752576453000},"page":"152390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multiple myeloma: Insights into underlying mechanisms, advances in diagnostic and therapeutic modalities"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0859-5603","authenticated-orcid":false,"given":"Rohitash","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra Kumar","family":"Chaudary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushboo","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Dhamija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj Kumar","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uttam Kumar","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.seminoncol.2025.152390_sbref0001","first-page":"578","article-title":"Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies","volume":"12","author":"Kazandjian","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0002","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Prim"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival, a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/ijc.30218","article-title":"Pesticide exposures and the risk of multiple myeloma in men: an analysis of the North American Pooled Project","volume":"139","author":"Presutti","year":"2016","journal-title":"Int J cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-08107-8","article-title":"Author correction: identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma","volume":"10","author":"Went","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0007","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/1878-0261.12772","article-title":"Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms","volume":"15","author":"Friedenreich","year":"2021","journal-title":"Mol Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0009","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canep.2019.02.010","article-title":"Distribution of multiple myeloma in India: heterogeneity in incidence across age, sex and geography","volume":"59","author":"Bora","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152390_bib0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101242","article-title":"From MGUS to multiple myeloma: unraveling the unknown of precursor states","volume":"68","author":"Hevroni","year":"2024","journal-title":"Blood Rev"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0012","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0013","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamainternmed.2024.8124","article-title":"Diagnosis and management of monoclonal gammopathy of undetermined significance: a review","volume":"185","author":"Liu","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"25","key":"10.1016\/j.seminoncol.2025.152390_bib0014","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0015","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0016","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3322\/caac.21252","article-title":"Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back","volume":"64","author":"Bianchi","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0017","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0018","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","article-title":"Myeloma as a model for the process of metastasis: implications for therapy","volume":"120","author":"Ghobrial","year":"2012","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.seminoncol.2025.152390_bib0019","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-12-784132","article-title":"The interplay of leukemia cells and the bone marrow microenvironment","volume":"131","author":"Duarte","year":"2018","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.seminoncol.2025.152390_bib0020","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.devcel.2021.05.018","article-title":"Niches that regulate stem cells and hematopoiesis in adult bone marrow","volume":"56","author":"Comazzetto","year":"2021","journal-title":"Dev Cell"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17040653","article-title":"Multiple myeloma insights from single-cell analysis: clonal evolution, the microenvironment, therapy evasion, and clinical implications","volume":"17","author":"Li","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37699-z","article-title":"Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma","volume":"14","author":"Kuang","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0023","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152390_bib0024","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/aje\/kwr454","article-title":"Differential associations between the food environment near schools and childhood overweight across race\/ethnicity, gender, and grade","volume":"175","author":"S\u00e1nchez","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"16","key":"10.1016\/j.seminoncol.2025.152390_bib0025","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.seminoncol.2025.152390_bib0026","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0027","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0028","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/s41375-023-01874-4","article-title":"Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders","volume":"37","author":"Shah","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0029","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.14356","article-title":"The role of lifestyle and environmental factors in the pathogenesis of multiple myeloma","volume":"114","author":"Suska","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0030","first-page":"573","article-title":"The genetic and molecular drivers of Multiple myeloma: current insights, clinical implications, and the path forward","volume":"17","author":"Ram","year":"2024","journal-title":"Pharmacogenomics Pers Med"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0031","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/0092-8674(92)90586-2","article-title":"Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells","volume":"71","author":"Hartwell","year":"1992","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0032","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029611","article-title":"Chromosomal instability as a driver of tumor heterogeneity and evolution","volume":"7","author":"Bakhoum","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0033","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrclinonc.2017.198","article-title":"Determinants and clinical implications of chromosomal instability in cancer","volume":"15","author":"Sansregret","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00302","article-title":"Multi-layered cancer chromosomal instability phenotype","volume":"3","author":"Roschke","year":"2013","journal-title":"Front Oncol"},{"issue":"22","key":"10.1016\/j.seminoncol.2025.152390_bib0035","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cub.2009.09.055","article-title":"Deviant kinetochore microtubule dynamics underlie chromosomal instability","volume":"19","author":"Bakhoum","year":"2009","journal-title":"Curr Biol"},{"issue":"7383","key":"10.1016\/j.seminoncol.2025.152390_bib0036","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nature10802","article-title":"DNA breaks and chromosome pulverization from errors in mitosis","volume":"482","author":"Crasta","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0037","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.cell.2011.07.042","article-title":"Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements","volume":"146","author":"Liu","year":"2011","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152390_bib0038","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2010-02-269126","article-title":"Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug","volume":"116","author":"Hu","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13020215","article-title":"Treatment strategies considering micro-environment and clonal evolution in multiple myeloma","volume":"13","author":"Suzuki","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.devcel.2018.02.002","article-title":"Cellular stress associated with aneuploidy","volume":"44","author":"Zhu","year":"2018","journal-title":"Dev Cell"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152390_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9110151","article-title":"Evolving therapeutic strategies to exploit chromosome instability in cancer","volume":"9","author":"Thompson","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0042","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0043","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41568-020-00321-1","article-title":"Aneuploidy as a promoter and suppressor of malignant growth","volume":"21","author":"Vasudevan","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"10.1016\/j.seminoncol.2025.152390_sbref0002a","first-page":"3854","article-title":"Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization","volume":"55","author":"Drach","year":"1995","journal-title":"Cancer Res"},{"issue":"48","key":"10.1016\/j.seminoncol.2025.152390_bib0045","doi-asserted-by":"crossref","first-page":"30566","DOI":"10.1073\/pnas.2009506117","article-title":"Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division","volume":"117","author":"Replogle","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"44","key":"10.1016\/j.seminoncol.2025.152390_bib0046","doi-asserted-by":"crossref","first-page":"78234","DOI":"10.18632\/oncotarget.20829","article-title":"Chromosomal instability and acquired drug resistance in multiple myeloma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152390_bib0047","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","article-title":"Genetics of multiple myeloma: another heterogeneity level?","volume":"125","author":"Corre","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0048","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0049","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0051","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2016.12.004","article-title":"Single-chromosome gains commonly function as tumor suppressors","volume":"31","author":"Sheltzer","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0052","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152390_bib0053","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","article-title":"The t(4;14) translocation in Myeloma dysregulates both FGFR3and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts","volume":"92","author":"Chesi","year":"1998","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0054","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0055","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ng.2583","article-title":"The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma","volume":"45","author":"Weinhold","year":"2013","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0056","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0057","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood.2024024299","article-title":"The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma","volume":"144","author":"Cirrincione","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.seminoncol.2025.152390_bib0058","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0059","first-page":"1393","article-title":"Effect of 13q deletion on IL-6 production in patients with multiple myeloma: a hypothesis may hold true","volume":"60","author":"Neemat","year":"2014","journal-title":"Clin Lab"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0060","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152390_bib0061","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/s41375-018-0103-3","article-title":"Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms","volume":"32","author":"Hoang","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0062","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/10428194.2020.1849681","article-title":"Interdisciplinary approach to multiple myeloma\u2014time to diagnosis and warning signs","volume":"62","author":"Herget","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0063","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"7483","key":"10.1016\/j.seminoncol.2025.152390_bib0064","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature12984","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_sbref0003a","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0066","first-page":"109","article-title":"Assessment of bone marrow biopsy and cytogenetic findings in patients with multiple myeloma","volume":"39","author":"\u015eeyhanl\u0131","year":"2022","journal-title":"Turkish J Haematol Off J Turkish Soc Haematol"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0067","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/jclinpath-2021-207524","article-title":"Evaluation of an open-source machine-learning tool to quantify bone marrow plasma cells","volume":"74","author":"Baranova","year":"2021","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_sbref0004e","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.seminoncol.2025.152390_bib0069","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.seminoncol.2025.152390_bib0070","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0071","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.seminoncol.2025.152390_bib0072","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1182\/bloodadvances.2023011096","article-title":"Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS","volume":"7","author":"Guo","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0073","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3109\/13813455.2011.582875","article-title":"Epidemiology of multiple myeloma and the role of M-band detection on serum electrophoresis in a small developing country. A retrospective study","volume":"117","author":"Nayak","year":"2011","journal-title":"Arch Physiol Biochem"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0074","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1021\/acs.jproteome.9b00705","article-title":"Integrating serum protein electrophoresis with mass spectrometry, A new workflow for M-protein detection and quantification","volume":"19","author":"Zajec","year":"2020","journal-title":"J Proteome Res"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0075","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.25819","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","volume":"95","author":"Gertz","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0076","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.pan.2021.03.001","article-title":"Serum free light chain assessment in type 1 autoimmune pancreatitis","volume":"21","author":"Ikemune","year":"2021","journal-title":"Pancreatology"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0077","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0078","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.talanta.2019.03.067","article-title":"Nanoporous silica coupled MALDI-TOF MS detection of Bence-Jones proteins in human urine for diagnosis of multiple myeloma","volume":"200","author":"Long","year":"2019","journal-title":"Talanta"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0079","first-page":"380","article-title":"The clinical significance of cytogenetic studies in 100 patients with multiple myeloma","volume":"66","author":"Dewald","year":"1985","journal-title":"Plasma Cell Leukemia, or Amyloidosis. Blood."},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2402797","article-title":"Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma","volume":"17","author":"Debes-Marun","year":"2003","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0081","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood-2014-07-584268","article-title":"Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations","volume":"125","author":"Pawlyn","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0082","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0083","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ijlh.12882","article-title":"Recent advances in cytogenetic characterization of multiple myeloma","volume":"41","author":"Saxe","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0084","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/mco.2020.2039","article-title":"The role of CT in PET\/CT for assessing diffuse infiltration of bone marrow in multiple myeloma using the Durie-Salmon PLUS staging system","volume":"13","author":"Wang","year":"2020","journal-title":"Mol Clin Oncol"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152390_bib0085","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.ejrad.2014.09.012","article-title":"State of the art imaging of multiple myeloma: comparative review of FDG PET\/CT imaging in various clinical settings","volume":"83","author":"Mesguich","year":"2014","journal-title":"Eur J Radiol"},{"issue":"1097","key":"10.1016\/j.seminoncol.2025.152390_bib0086","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180822","article-title":"Detection of avascular necrosis on routine diffusionweighted whole body MRI in patients with multiple myeloma","volume":"92","author":"Ahmed","year":"2019","journal-title":"Br J Radiol"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0087","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18 F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0088","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cpet.2019.03.005","article-title":"Fluorodeoxyglucose-PET\/computed tomography as a predictor of prognosis in multiple myeloma","volume":"14","author":"Nanni","year":"2019","journal-title":"PET Clin"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152390_bib0089","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00259-016-3392-7","article-title":"18F-fluorocholine versus 18F-fluorodeoxyglucose for PET\/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study","volume":"43","author":"Cassou-Mounat","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0090","first-page":"33","article-title":"The clinical use of PET with 11C-acetate","volume":"2","author":"Grassi","year":"2012","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0091","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2967\/jnumed.113.131169","article-title":"11C-acetate PET\/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET\/CT","volume":"55","author":"Ho","year":"2014","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0092","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12149-014-0931-9","article-title":"Comparison of (11)C-4\u2019-thiothymidine, (11)C-methionine, and (18)F-FDG PET\/CT for the detection of active lesions of multiple myeloma","volume":"29","author":"Okasaki","year":"2015","journal-title":"Ann Nucl Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0093","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-018-3080-3","article-title":"Health economic evaluations based on routine data in Germany: a systematic review","volume":"18","author":"Gansen","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0094","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[68 Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma\u2014comparison to [18 F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10456-024-09910-2","article-title":"The role of vasculature and angiogenesis in respiratory diseases","volume":"27","author":"Ackermann","year":"2024","journal-title":"Angiogenesis"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0096","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041779","article-title":"Angiogenesis: biology and pathology, second edition","volume":"15","author":"Bielenberg","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0097","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10456-017-9569-2","article-title":"History and conceptual developments in vascular biology and angiogenesis research: a personal view","volume":"20","author":"Bikfalvi","year":"2017","journal-title":"Angiogenesis"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0098","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189079","article-title":"VEGF signaling: role in angiogenesis and beyond","volume":"1879","author":"Shaw","year":"2024","journal-title":"Biochim Biophys Acta\u2014Rev Cancer"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.leu.2404067","article-title":"Bone marrow angiogenesis in multiple myeloma","volume":"20","author":"Vacca","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0101","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2003-11-3811","article-title":"Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression","volume":"104","author":"Kumar","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0102","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2008-10-184226","article-title":"Induction of angiogenesis by normal and malignant plasma cells","volume":"114","author":"Hose","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0103","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000353312","article-title":"Angiogenesis in multiple myeloma","volume":"99","author":"Vacca","year":"2014","journal-title":"Chem Immunol Allergy"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0104","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12307-011-0072-9","article-title":"Angiogenesis and multiple myeloma","volume":"4","author":"Giuliani","year":"2011","journal-title":"Cancer Microenviron"},{"issue":"8\u20139","key":"10.1016\/j.seminoncol.2025.152390_bib0105","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.clinbiochem.2011.01.010","article-title":"Angiopoietin-2: a potential novel diagnostic marker in multiple myeloma","volume":"44","author":"Joshi","year":"2011","journal-title":"Clin Biochem"},{"issue":"19","key":"10.1016\/j.seminoncol.2025.152390_bib0106","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"G-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0107","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152390_bib0108","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0109","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3324\/haematol.2022.280629","article-title":"A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed\/refractory multiple myeloma: results from phase I clinical trials","volume":"107","author":"Yang","year":"2022","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00505-4","article-title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0111","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.889","article-title":"Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma","volume":"6","author":"Terpos","year":"2024","journal-title":"EJHaem"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0112","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ajh.27225","article-title":"Soluble B-cell maturation antigen in multiple myeloma","volume":"99","author":"Costa","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0113","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/apha.12681","article-title":"MicroRNAs in metabolism","volume":"219","author":"Vienberg","year":"2017","journal-title":"Acta Physiol (Oxf)"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152390_bib0114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083545","article-title":"miRNA-720 controls stem cell phenotype, proliferation and differentiation of human dental pulp cells","volume":"8","author":"Hara","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0115","first-page":"779","article-title":"MicroRNA\u201193 inhibits chondrocyte apoptosis and inflammation in osteoarthritis by targeting the TLR4\/NF\u2011\u03bab signaling pathway","volume":"43","author":"Ding","year":"2019","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0116","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-pathol-012513-104715","article-title":"MicroRNAs in cancer","volume":"9","author":"Di Leva","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0117","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.753931","article-title":"Interactions among lncRNA\/circRNA, miRNA, and mRNA in musculoskeletal degenerative diseases","volume":"9","author":"Zheng","year":"2021","journal-title":"Front cell Dev Biol"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152390_bib0118","doi-asserted-by":"crossref","DOI":"10.3390\/v12121440","article-title":"miRNAs as potential biomarkers for viral Hepatitis B and C","volume":"12","author":"Loureiro","year":"2020","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0119","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.109994","article-title":"Current knowledge on therapeutic, diagnostic, and prognostics applications of exosomes in multiple myeloma: opportunities and challenges","volume":"756","author":"Ramezani","year":"2024","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154704","article-title":"miRNAs driving diagnosis, progression, and drug resistance in multiple myeloma","volume":"248","author":"Elkady","year":"2023","journal-title":"Pathol Res Pract"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152390_bib0122","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41417-020-00291-4","article-title":"Roles of miRNA dysregulation in the pathogenesis of multiple myeloma","volume":"28","author":"Chen","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0123","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70036","article-title":"MicroRNA profiling of bone marrow plasma extracellular vesicles in multiple myeloma, extramedullary disease, and plasma cell leukemia","volume":"43","author":"Gregorova","year":"2025","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0124","doi-asserted-by":"crossref","DOI":"10.3390\/genes14010100","article-title":"MYC causes multiple myeloma progression via attenuating TP53-induced MicroRNA-34 expression","volume":"14","author":"Murakami","year":"2023","journal-title":"Genes (Basel)"},{"issue":"35","key":"10.1016\/j.seminoncol.2025.152390_bib0125","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis","volume":"105","author":"Pichiorri","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0126","doi-asserted-by":"crossref","DOI":"10.3390\/ncrna9060068","article-title":"Dysregulation of non-coding RNAs: roles of miRNAs and lncRNAs in the pathogenesis of multiple myeloma","volume":"9","author":"Ismail","year":"2023","journal-title":"Non-coding RNA"},{"issue":"41","key":"10.1016\/j.seminoncol.2025.152390_bib0127","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1038\/s41388-018-0359-0","article-title":"Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0128","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/leu.2017.91","article-title":"The emerging roles of tumor-derived exosomes in hematological malignancies","volume":"31","author":"Boyiadzis","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0129","doi-asserted-by":"crossref","DOI":"10.1186\/2050-7771-2-10","article-title":"Micro-RNAs, new performers in multiple myeloma bone marrow microenvironment","volume":"2","author":"Abdi","year":"2014","journal-title":"Biomark Res"},{"issue":"49","key":"10.1016\/j.seminoncol.2025.152390_bib0130","doi-asserted-by":"crossref","first-page":"51338","DOI":"10.1074\/jbc.M409293200","article-title":"Telosome, a mammalian telomere-associated complex formed by multiple telomeric proteins","volume":"279","author":"Liu","year":"2004","journal-title":"J Biol Chem"},{"issue":"15","key":"10.1016\/j.seminoncol.2025.152390_bib0131","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1016\/j.cell.2024.05.048","article-title":"TERT activation targets DNA methylation and multiple aging hallmarks","volume":"187","author":"Shim","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0132","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101411","article-title":"Exercise training increases telomerase reverse transcriptase gene expression and telomerase activity: a systematic review and meta-analysis","volume":"70","author":"Denham","year":"2021","journal-title":"Ageing Res Rev"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0133","doi-asserted-by":"crossref","first-page":"E351","DOI":"10.1002\/ijc.29101","article-title":"Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length","volume":"136","author":"Campa","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0134","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.16404","article-title":"BIBR1532 inhibits proliferation and enhances apoptosis in multiple myeloma cells by reducing telomerase activity","volume":"11","author":"Zhang","year":"2023","journal-title":"PeerJ"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00462-y","article-title":"Genetically determined telomere length and multiple myeloma risk and outcome","volume":"11","author":"Giaccherini","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0136","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43141-7","article-title":"Telomere length and hTERT genetic variants as potential prognostic markers in multiple myeloma","volume":"13","author":"Dratwa","year":"2023","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0137","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0138","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-0304-7","article-title":"A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma","volume":"10","author":"Rajeev Krishnan","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0139","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101146","article-title":"Tracking myeloma tumor DNA in peripheral blood","volume":"33","author":"Waldschmidt","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-020-01897-9","article-title":"Liquid biopsies for multiple myeloma in a time of precision medicine","volume":"98","author":"Ferreira","year":"2020","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0141","first-page":"2695","article-title":"Patient-derived extracellular vesicles proteins as new biomarkers in multiple myeloma\u2014a real-world study","volume":"0","author":"Ferreira","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0142","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41375-021-01492-y","article-title":"Cell-free DNA for the detection of emerging treatment failure in relapsed\/refractory multiple myeloma","volume":"36","author":"Waldschmidt","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0143","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00277-022-04771-5","article-title":"Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells","volume":"101","author":"Mack","year":"2022","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152390_bib0144","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152390_bib0145","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0146","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1182\/blood-2023-185699","article-title":"Multicenter open label phase 3 benefit study of Isatuximab plus Lenalidomide and Dexamethasone with\/without Bortezomib in the treatment of newly diagnosed non-frail transplant ineligible multiple myeloma elderly patients. IFM2020-05","volume":"142","author":"Bobin","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0147","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bjh.18295","article-title":"Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review","volume":"199","author":"McCaughan","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0148","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-10907-1","article-title":"Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"23","author":"Lin","year":"2023","journal-title":"BMC Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.seminoncol.2025.152390_bib0149","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0150","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ajh.26161","article-title":"Current approaches to management of high-risk multiple myeloma","volume":"96","author":"Goldman-Mazur","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0151","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056147","article-title":"F railty-adjusted therapy i n T ransplant N on- E ligible patient s with newly diagno s ed Multiple myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial","volume":"12","author":"Coulson","year":"2022","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0152","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152390_bib0153","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152390_bib0154","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152390_bib0155","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/cncr.25743","article-title":"The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens","volume":"117","author":"Benevolo","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0156","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0157","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study","volume":"177","author":"Dimopoulos","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152390_bib0158","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (E1A11): a multicenter, open label, phase 3, randomized, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0159","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.seminoncol.2025.152390_bib0160","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0161","first-page":"46","article-title":"Treatment of older adult or frail patients with multiple myeloma","volume":"2021","author":"Grant","year":"2021","journal-title":"Hematol (United States)"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0162","unstructured":"Manier S, Lambert J, Hulin C, et al. A Dexamethasone sparing-regimen with Daratumumab and Lenalidomide in frail patients with newly-diagnosed multiple myeloma: the IFM2017-03 phase 3 trial. 2025 [Accessed May 27, 2025]; Available from: https:\/\/papers.ssrn.com\/abstract=5201850"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0163","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3324\/haematol.2019.226407","article-title":"Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial","volume":"105","author":"Bringhen","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0164","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O\u2019Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0165","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-021-00344-2","article-title":"The changing landscape of relapsed and\/or refractory multiple myeloma (MM): fundamentals and controversies","volume":"10","author":"Hern\u00e1ndez-Rivas","year":"2022","journal-title":"Biomark Res"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0166","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41375-020-0868-z","article-title":"Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0167","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00948-5","article-title":"Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk","volume":"13","author":"Weisel","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0168","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with Carfilzomib, Lenalidomide, and Dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0169","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0170","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0171","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.clml.2019.04.018","article-title":"Carfilzomib-Dexamethasone versus Bortezomib-Dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups","volume":"19","author":"Orlowski","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0172","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2022.01.011","article-title":"Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma","volume":"22","author":"Dimopoulos","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"10.1016\/j.seminoncol.2025.152390_bib0173","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0174","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70585","article-title":"Treatment of multiple myeloma in patients refractory to Daratumumab\/Anti-CD38 monoclonal antibodies: a systematic review","volume":"14","author":"Tan","year":"2025","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0175","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152390_bib0176","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0177","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08451-x","article-title":"Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019","volume":"21","author":"Balmaceda","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0178","first-page":"1217","article-title":"Efficacy and safety of plasmapheresis without plasma transfusion tandem with chemotherapy to treat multiple myeloma","volume":"27","author":"Guo","year":"2022","journal-title":"Hematol (United Kingdom)"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0179","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/stem.5530110203","article-title":"Recombinant human erythropoietin and the anemia of multiple myeloma","volume":"11","author":"Barlogie","year":"1993","journal-title":"Stem Cells"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152390_bib0180","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood.V27.3.328.328","article-title":"A controlled trial of urethane treatment in multiple myeloma","volume":"27","author":"Holland","year":"1966","journal-title":"Blood"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0181","unstructured":"Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-phenylalanine mustard (NSC-8806). [Accessed July 11, 2022]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/13867794\/"},{"issue":"8354","key":"10.1016\/j.seminoncol.2025.152390_bib0182","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"2","author":"Mcelwain","year":"1983","journal-title":"Lancet (London, England)"},{"issue":"21","key":"10.1016\/j.seminoncol.2025.152390_bib0183","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"issue":"5971","key":"10.1016\/j.seminoncol.2025.152390_bib0184","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.seminoncol.2025.152390_bib0185","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0186","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6320329","article-title":"Effect of autologous stem cell transplantation combined with modified VTD regimen on elderly patients with multiple myeloma and its influence on miRNA cytokines","volume":"2022","author":"Bai","year":"2022","journal-title":"Comput Math Methods Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_sbref0025a","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/16078454.2021.2019364","article-title":"Pomalidomide-based therapy for extramedullary multiple myeloma","volume":"27","author":"Li","year":"2022","journal-title":"Hematology"},{"issue":"10272","key":"10.1016\/j.seminoncol.2025.152390_bib0188","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152390_bib0189","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2217\/fon-2020-0907","article-title":"Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma","volume":"17","author":"Touzeau","year":"2021","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12185-019-02757-0","article-title":"Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan","volume":"111","author":"Kubo","year":"2020","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152390_bib0191","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/adc.62.12.1224","article-title":"Longitudinal study of height and weight at adolescence","volume":"62","author":"Buckler","year":"1987","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0192","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"Van De Donk","year":"2018","journal-title":"Blood"},{"issue":"10214","key":"10.1016\/j.seminoncol.2025.152390_bib0193","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0194","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152390_bib0195","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0196","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"issue":"22","key":"10.1016\/j.seminoncol.2025.152390_bib0197","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.seminoncol.2025.152390_bib0198","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-Human study of ABBV-383, a B-cell maturation antigen\u202f\u00d7\u202fCD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D\u2019souza","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0199","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti\u2013B-cell maturation antigen bite molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2024.11.002","article-title":"Therapeutic targeting of exportin-1 beyond nuclear export","volume":"46","author":"Chen","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"14","key":"10.1016\/j.seminoncol.2025.152390_bib0201","doi-asserted-by":"crossref","DOI":"10.1093\/ajhp\/zxac091","article-title":"New and emerging pharmacotherapies for the management of multiple myeloma","volume":"79","author":"Moore","year":"2022","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0202","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02305-4","article-title":"Selinexor plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study","volume":"20","author":"Qiu","year":"2022","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0203","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/j.clml.2022.01.014","article-title":"Guidance for use and dosing of Selinexor in multiple Myeloma in 2021: consensus from International Myeloma Foundation Expert roundtable","volume":"22","author":"Nooka","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0204","doi-asserted-by":"crossref","DOI":"10.3390\/cells14060430","article-title":"Selinexor\u2019s immunomodulatory impact in advancing multiple myeloma treatment","volume":"14","author":"Tasbihi","year":"2025","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152390_bib0205","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0206","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00277-021-04555-3","article-title":"Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed\/refractory multiple myeloma patients-a single-center retrospective study","volume":"100","author":"Regidor","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0207","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2022.1610276","article-title":"Targeted venetoclax therapy in t(11;14) multiple myeloma: real world data from seven Hungarian centers","volume":"28","author":"Szita","year":"2022","journal-title":"Pathol Oncol Res"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0208","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.53","article-title":"New investigational drugs with single-agent activity in multiple myeloma","volume":"6","author":"Rajan","year":"2016","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152390_bib0209","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152390_bib0210","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1084\/jem.192.11.1677","article-title":"A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth","volume":"192","author":"Rennert","year":"2000","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152390_bib0211","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.2023021221","article-title":"CAR T-cell therapy in multiple myeloma: mission accomplished?","volume":"143","author":"Rasche","year":"2024","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.seminoncol.2025.152390_bib0212","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0213","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0214","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152390_bib0215","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0216","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0217","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/ejh.14208","article-title":"Ocular adverse events following CAR-T cell therapy: a pharmacovigilance study and systematic review","volume":"113","author":"Frey","year":"2024","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0218","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0219","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/onco.13592","article-title":"EMA review of Belantamab Mafodotin (Blenrep) for the treatment of adult patients with relapsed\/refractory multiple myeloma","volume":"26","author":"Tzogani","year":"2021","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0220","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/cpt.2409","article-title":"Exposure-response analyses for therapeutic dose selection of Belantamab Mafodotin in patients with relapsed\/refractory multiple myeloma","volume":"110","author":"Ferron-Brady","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152390_bib0221","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0222","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152390_bib0223","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0224","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2018.03.002","article-title":"Next-generation proteasome inhibitors for cancer therapy","volume":"198","author":"Park","year":"2018","journal-title":"Transl Res"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113963","article-title":"Identification and in-vitro analysis of potential proteasome inhibitors targeting PSM\u03b25 for multiple myeloma","volume":"157","author":"Yadav","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0226","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood.2023020276","article-title":"Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency","volume":"143","author":"Leblay","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0227","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-024-00507-5","article-title":"Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives","volume":"13","author":"Pu","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0228","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41375-019-0493-x","article-title":"Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling","volume":"34","author":"Ho","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.seminoncol.2025.152390_bib0229","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2146\/ajhp150487","article-title":"Panobinostat: a histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma","volume":"73","author":"Wahaib","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.seminoncol.2025.152390_bib0230","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/ITT.S306103","article-title":"Immunotherapy of Multiple myeloma: promise and challenges","volume":"10","author":"Abramson","year":"2021","journal-title":"ImmunoTargets Ther"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152390_bib0231","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/bjh.17076","article-title":"A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients","volume":"191","author":"Bird","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152390_bib0232","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1470-2045(20)30680-X","article-title":"Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study","volume":"22","author":"Laubach","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152390_bib0233","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","article-title":"Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial","volume":"3","author":"San-Miguel","year":"2016","journal-title":"Lancet Haematol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377542500082X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377542500082X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T20:54:19Z","timestamp":1752699259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377542500082X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":233,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S009377542500082X"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152390","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple myeloma: Insights into underlying mechanisms, advances in diagnostic and therapeutic modalities","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152390"}}